Protein
Protein on GLP-1: targets, sources, pacing, tracking
Across the STEP and SURMOUNT trials, an estimated 25–40% of total weight lost on semaglutide and tirzepatide is lean tissue. Adequate protein intake plus resistance training are the two most-cited modifiable inputs for preserving lean mass under rapid weight loss. These articles cover starting protein targets, sources, pacing across smaller meals, and tracking when meal sizes are unreliable.
Tracking protein when you eat less: the case for visual logging
Why traditional typed food logs become unreliable on GLP-1, and why photo-first logging fits the smaller-meal pattern. Practical comparison with manual tracking. Brief audit periods as an alternative.
Protein and meal-replacement shakes on GLP-1
Liquid protein and meal-replacement shakes on GLP-1 receptor agonist therapy. What to look for in a quality shake. Whey, casein, plant-protein isolate options. Tolerance considerations. Common product categories.
Protein quality and leucine thresholds: the per-meal anabolic signal
Per-meal leucine threshold of approximately 2.5-3 g is the threshold for stimulating muscle protein synthesis. How different protein sources reach (or do not reach) this threshold at different per-meal portions. Practical implications for GLP-1 patients with reduced meal capacity.
Protein pacing when appetite is low: distributing intake across the day
Distribution of protein across the day matters for muscle protein synthesis stimulation. Practical pacing patterns when meal capacity is reduced. Bedtime protein. Front-loading vs even-distribution. Worked examples.
Whey vs plant protein on GLP-1: practical comparison
Whey, casein, and other animal proteins versus pea, soy, rice, hemp, and other plant proteins on GLP-1. Completeness, leucine content, digestibility, satiety implications, and practical considerations for patients with smaller meal capacity.
Protein targets on GLP-1: a starting framework
Practical starting protein-target ranges for adults under hypocaloric conditions on GLP-1 receptor agonist therapy, with explicit caveats. Older-adult considerations. Resistance-training context. Renal-disease caveats. The keystone article on protein for GLP-1 patients.